MitraClip (R) therapy in patients with end-stage systolic heart failure

Olaf Franzen; Jan van der Heyden; Stephan Baldus; Michael Schlueter; Wolfgang Schillinger; Christian Butter; Rainer Hoffmann; Roberto Corti; Giovanni Pedrazzini; Martin J. Swaans; Michael Neuss; Volker Rudolph; Daniel Suerder; Juerg Gruenenfelder; Christine Eulenburg; Hermann Reichenspurner; Thomas Meinertz; Angelo Auricchio

doi:10.1093/eurjhf/hfr029

MitraClip (R) therapy in patients with end-stage systolic heart failure

Olaf Franzen^*, Jan van der Heyden, Stephan Baldus, Michael Schlueter, Wolfgang Schillinger, Christian Butter, Rainer Hoffmann, Roberto Corti, Giovanni Pedrazzini, Martin J. Swaans, Michael Neuss, Volker Rudolph, Daniel Suerder, Juerg Gruenenfelder, Christine Eulenburg, Hermann Reichenspurner, Thomas Meinertz, Angelo Auricchio

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

277 Citations (Scopus)

Abstract

Aims To assess the feasibility, short-term durability and clinical outcomes of MitraClip (R) therapy for mitral regurgitation (MR) in patients with end-stage heart failure and a severely reduced left ventricular (LV) ejection fraction.

Methods and results We analysed retrospectively collected data from seven European centres. Included in the study were 50 heart failure patients [ mean age 70 +/- 11 years, 38 men (76%)] with a LV ejection fraction

Conclusion MitraClip (R) therapy reduces functional MR in patients with end-stage heart failure and marked LV dysfunction and entails clinical benefit at 6 months.

Original language	English
Pages (from-to)	569-576
Number of pages	8
Journal	European Journal of Heart Failure
Volume	13
Issue number	5
DOIs	https://doi.org/10.1093/eurjhf/hfr029
Publication status	Published - May-2011
Externally published	Yes

Keywords

Heart failure
Heart valves
Mitral regurgitation
Catheter-based therapy
ISCHEMIC MITRAL REGURGITATION
CARDIAC RESYNCHRONIZATION THERAPY
VALVE ANNULOPLASTY
CLINICAL-TRIAL
SEVERITY
IMPACT
DYSFUNCTION
REPAIR
ECHOCARDIOGRAPHY
RISK

Access to Document

10.1093/eurjhf/hfr029

Handle.net

Persistent link

Cite this

Franzen, O., van der Heyden, J., Baldus, S., Schlueter, M., Schillinger, W., Butter, C., Hoffmann, R., Corti, R., Pedrazzini, G., Swaans, M. J., Neuss, M., Rudolph, V., Suerder, D., Gruenenfelder, J., Eulenburg, C., Reichenspurner, H., Meinertz, T., & Auricchio, A. (2011). MitraClip (R) therapy in patients with end-stage systolic heart failure. European Journal of Heart Failure, 13(5), 569-576. https://doi.org/10.1093/eurjhf/hfr029

@article{b91a05bf851446b4b9ed1cbcb37d3d4a,

title = "MitraClip (R) therapy in patients with end-stage systolic heart failure",

abstract = "Aims To assess the feasibility, short-term durability and clinical outcomes of MitraClip (R) therapy for mitral regurgitation (MR) in patients with end-stage heart failure and a severely reduced left ventricular (LV) ejection fraction.Methods and results We analysed retrospectively collected data from seven European centres. Included in the study were 50 heart failure patients [ mean age 70 +/- 11 years, 38 men (76%)] with a LV ejection fractionConclusion MitraClip (R) therapy reduces functional MR in patients with end-stage heart failure and marked LV dysfunction and entails clinical benefit at 6 months.",

keywords = "Heart failure, Heart valves, Mitral regurgitation, Catheter-based therapy, ISCHEMIC MITRAL REGURGITATION, CARDIAC RESYNCHRONIZATION THERAPY, VALVE ANNULOPLASTY, CLINICAL-TRIAL, SEVERITY, IMPACT, DYSFUNCTION, REPAIR, ECHOCARDIOGRAPHY, RISK",

author = "Olaf Franzen and {van der Heyden}, Jan and Stephan Baldus and Michael Schlueter and Wolfgang Schillinger and Christian Butter and Rainer Hoffmann and Roberto Corti and Giovanni Pedrazzini and Swaans, {Martin J.} and Michael Neuss and Volker Rudolph and Daniel Suerder and Juerg Gruenenfelder and Christine Eulenburg and Hermann Reichenspurner and Thomas Meinertz and Angelo Auricchio",

year = "2011",

month = may,

doi = "10.1093/eurjhf/hfr029",

language = "English",

volume = "13",

pages = "569--576",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Wiley",

number = "5",

}

Franzen, O, van der Heyden, J, Baldus, S, Schlueter, M, Schillinger, W, Butter, C, Hoffmann, R, Corti, R, Pedrazzini, G, Swaans, MJ, Neuss, M, Rudolph, V, Suerder, D, Gruenenfelder, J, Eulenburg, C, Reichenspurner, H, Meinertz, T & Auricchio, A 2011, 'MitraClip (R) therapy in patients with end-stage systolic heart failure', European Journal of Heart Failure, vol. 13, no. 5, pp. 569-576. https://doi.org/10.1093/eurjhf/hfr029

TY - JOUR

T1 - MitraClip (R) therapy in patients with end-stage systolic heart failure

AU - Franzen, Olaf

AU - van der Heyden, Jan

AU - Baldus, Stephan

AU - Schlueter, Michael

AU - Schillinger, Wolfgang

AU - Butter, Christian

AU - Hoffmann, Rainer

AU - Corti, Roberto

AU - Pedrazzini, Giovanni

AU - Swaans, Martin J.

AU - Neuss, Michael

AU - Rudolph, Volker

AU - Suerder, Daniel

AU - Gruenenfelder, Juerg

AU - Eulenburg, Christine

AU - Reichenspurner, Hermann

AU - Meinertz, Thomas

AU - Auricchio, Angelo

PY - 2011/5

Y1 - 2011/5

N2 - Aims To assess the feasibility, short-term durability and clinical outcomes of MitraClip (R) therapy for mitral regurgitation (MR) in patients with end-stage heart failure and a severely reduced left ventricular (LV) ejection fraction.Methods and results We analysed retrospectively collected data from seven European centres. Included in the study were 50 heart failure patients [ mean age 70 +/- 11 years, 38 men (76%)] with a LV ejection fractionConclusion MitraClip (R) therapy reduces functional MR in patients with end-stage heart failure and marked LV dysfunction and entails clinical benefit at 6 months.

AB - Aims To assess the feasibility, short-term durability and clinical outcomes of MitraClip (R) therapy for mitral regurgitation (MR) in patients with end-stage heart failure and a severely reduced left ventricular (LV) ejection fraction.Methods and results We analysed retrospectively collected data from seven European centres. Included in the study were 50 heart failure patients [ mean age 70 +/- 11 years, 38 men (76%)] with a LV ejection fractionConclusion MitraClip (R) therapy reduces functional MR in patients with end-stage heart failure and marked LV dysfunction and entails clinical benefit at 6 months.

KW - Heart failure

KW - Heart valves

KW - Mitral regurgitation

KW - Catheter-based therapy

KW - ISCHEMIC MITRAL REGURGITATION

KW - CARDIAC RESYNCHRONIZATION THERAPY

KW - VALVE ANNULOPLASTY

KW - CLINICAL-TRIAL

KW - SEVERITY

KW - IMPACT

KW - DYSFUNCTION

KW - REPAIR

KW - ECHOCARDIOGRAPHY

KW - RISK

U2 - 10.1093/eurjhf/hfr029

DO - 10.1093/eurjhf/hfr029

M3 - Article

SN - 1388-9842

VL - 13

SP - 569

EP - 576

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 5

ER -

MitraClip (R) therapy in patients with end-stage systolic heart failure

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this